Introduction {#s1}
============

Vonoprazan fumarate (TAK-438) is a potassium-competitive acid blocker (P-CAB) that was developed as a novel acid-suppressing drug and launched in 2015 ([@B9]). As a potential alternative to proton-pump inhibitors (PPIs), vonoprazan has been verified to be superior to conventional PPIs or even more effective in distinct gastric acid-related clinical indications. A phase III multicenter study demonstrated that there was no significant difference between vonoprazan and lansoprazole in treating erosive esophagitis ([@B37]). In terms of preventing the recurrence of low-dose or long-term aspirin-associated ulcers, vonoprazan has proven to be as effective as lansoprazole ([@B18]). The superior effect to rabeprazole was observed in healing artificial ulcer after endoscopic submucosal dissection ([@B41]). Since PPIs play a vital role in helping to eradicate *Helicobacter pylori* infection, vonoprazan has been applied in similar trails and is considered to be a substitute for PPIs in resistant groups ([@B25]).

Additionally, regarding the pharmacokinetic profile, vonoprazan exhibits some advantages over PPIs e.g., it takes effect more quickly, suppresses acid secretory more potently, and exhibits better tolerability ([@B13]). Specifically, 20 mg of vonoprazan once daily equals 60 mg of omeprazole b.i.d., which is also equivalent to esomeprazole 40 mg b.i.d. ([@B10]). It has been reported that vonoprazan is metabolized in two ways: the oxidative part by cytochrome P450 (CYP) enzyme isoforms and the nonoxidative part by sulfotransferase (SULT2A1) ([@B40]).

Cytochrome P450 (CYP), which represents a diverse group of enzymes found in liver microsomes, is significantly indispensable in biological metabolism ([@B36]) by metabolizing a large group of clinically used drugs ([@B33]). Because these enzymes can facilitate the elimination of various drugs, or modify their pharmacologic activities, the inhibition of these enzymes caused by drug coadministration or drug abuse can account for the increasing risk of adverse reactions ([@B34]). Human CYP includes 18 families and 44 subfamily members, which are categorized by amino acid similarities. Although the functions of genes in human cytochrome clusters contained differ from those of mice ([@B2]), human CYP have their functional counterparts in mice, providing us with efficient approaches for further drug-drug interaction (DDI) studies.

Thus, probe drug cocktails were developed to evaluate CYP activities and the potential of DDIs ([@B6]). After years of modification, the use of these cocktails is now a rapid, economical, and efficient approach for evaluating different CYP enzymes simultaneously but independently ([@B26]). To our best of our knowledge, no comprehensive DDI study of vonoprazan both *in vitro* and *in vivo* using the cocktails approach. Additionally, the existing results of vonoprazan DDIs were constrained to limited types of CYPs or were contradictory ([@B15]). Vonoprazan has not yet been launched in many countries, however, considering its effectiveness and safety, it has substantial potential to be widely utilized. Therefore, determining its DDIs will be beneficial for future clinical applications. Hence, in the present study, we explored the latent drug-drug interactions of vonoprazan. We chose phenacetin (CYP1A2), bupropion (CYP2B6), tolbutamide (CYP2C9), dextromethorphan (CYP2D6), midazolam (CYP3A), and chlorzoxazone (CYP2E1) as the core cocktail probe drugs, and ultrahigh-performance liquid chromatography coupled with triple quadrupole electrospray tandem mass spectrometry (UPLC-MS/MS) was performed to determine the results sensitively and reliably.

Materials and Methods {#s2}
=====================

Chemicals and Reagents {#s2_1}
----------------------

Phenacetin, bupropion, tolbutamide, dextromethorphan, midazolam, chlorzoxazone, and the diazepam (all purity\> 98%) that used as internal standards (ISs) were purchased from J&K Scientific Ltd. (Beijing, China). Vonoprazan was purchased from Beijing Sunflower Scientific Ltd. (Beijing, China). Hydroxybupropion and hydroxymidazolam were purchased from Sigma-Aldrich (St Louis, USA). Dextrorphan, hydroxytolbutamide, hydroxychlorzoxazone, and 4-acetamidophenol were purchased from Toronto Research Chemicals (Toronto, Canada). Reduced nicotinamide adenine dinucleotide phosphate (NADPH) was acquired from Roche Pharmaceuticals Ltd. (Basel, Switzerland). Ultra-pure water was produced by Milli-Q, a reagent-standard water purification system (Millipore, Bedford, USA). Acetonitrile and methanol that of high performance liquid chromatography (HPLC) grade were obtained from Merck Company (Darmstadt, Germany).

Instrumentation and Analytical Conditions {#s2_2}
-----------------------------------------

The UPLC-MS/MS conditions were established as described previously ([@B20]) and were modified by adding chlorzoxazone and replacing metoprolol with dextromethorphan in the probe drug system. Chromatographic separation was performed using the Acquity UPLC system (Waters Corp., Milford, MA, USA) and Acquity BEH C18 column (2.1 mm × 50 mm, 1.7 μM) at 40°C. The mobile phase comprising acetonitrile (A) and 0.1% formic acid water (B) was set with a 0.40-ml/min flow rate. The gradient program was applied as follows: 0--0.6 min, 10--50% A; 0.6--1 min, 50--80%; 1--2 min, 80--95% A; 2--2.5 min, 95% A; 2.5--2.6 min, 95--10% A; 2.6--3 min, 10% A. XEVO TQD triple quadrupole mass spectrometer was equipped with electrospray ionization (ESI), and multiple-reaction monitoring (MRM) mode was selected for quantitation. The transitions are shown in [**Table 1**](#T1){ref-type="table"}. MassLynx 4.1 software (Waters Corp., Milford, MA, USA) was used for data acquisition, and the UPLC-MS/MS chromatogram of blank plasma that was spiked with probe drugs and metabolites is shown below ([**Figure 1**](#f1){ref-type="fig"}).

###### 

The transitions of probe drugs.

  Compound           Parent   Daughter   Cone (V)   Collision (V)
  ------------------ -------- ---------- ---------- ---------------
  Phenacetin         180.05   109.94     35         20
  Bupropion          240.13   184.09     24         12
  Tolbutamide        271.2    155.1      30         15
  Dextromethorphan   272.19   147.01     45         30
  Diazepam           285.1    193.1      35         30
  Midazolam          326.02   290.99     50         28
  Chlorzoxazone      168.09   132.05     48         20

![UPLC-MS/MS chromatograms, blank plasma spiked with chlorzoxazone, midazolam, diazepam (IS), dextromethorphan, tolbutamide, bupropion, and phenacetin.](fphar-11-00053-g001){#f1}

Preparation of Rat Liver Microsomes {#s2_3}
-----------------------------------

The pooled rat liver microsomes (RLMs) obtained from eight rats, which were weighed and homogenized with cold 0.01 mM phosphate-buffered saline (PBS), containing 0.25 mM sucrose. After centrifugation for 15 min at 11,000 rpm, the supernatants were separated and transferred into new tubes for another 15-min centrifugation at 11,000 rpm. Next, ultracentrifugation was performed at 10,000 rpm at 4°C for 1 h., and the microsomal pellets were resuspended with cold 0.01 mM PBS and stored at −80°C ([@B35]). The protein concentration of RLMs was determined using the Bradford Protein Assay Kit (Thermo Scientific, Waltham, MA, USA).

*In Vitro* Interaction Studies in Rat Liver Microsomes {#s2_4}
------------------------------------------------------

Next, vonoprazan was applied as the inhibitor to determine the half maximal inhibitory concentration (IC50). The incubation mixture in a total volume of 200 μl contained 0.5 mg/ml of RLMs, 1 mM potassium phosphate buffer (pH 7.4), the probe drug mixture that dissolved by dimethyl sulfoxide (40, 20, 10, 100, 20, and 5 μM for phenacetin, bupropion, tolbutamide, dextromethorphan, chlorzoxazone, and midazolam, respectively), vonoprazan (1, 2.5, 5, 10, 25, 50, and 100 μM) and 1 mM NADPH ([@B28]). After preincubation in a shaking water bath at 37°C for 5 min, an NADPH-regenerating system was added to initiate the reaction in a final volume of 200 μl. The reaction was performed for 30 min, and was stopped by cooling to −80°C immediately. Next, 20 μl of internal standard (IS) working solution and 200 μl of acetonitrile were added. Centrifugation was performed at 13,000 rpm for 5 min after vortexing for 1 min. The supernatant mixture (2 μl) was injected into the UPLC--MS/MS system for analysis.

Pharmacokinetic Study of Vonoprazan {#s2_5}
-----------------------------------

Ten specific pathogen-free (SPF) grade Sprague--Dawley rats (male, 220 ± 20 g) were provided by Wenzhou Medical University Laboratory Animal Research Center. This study was carried out in accordance with the principles of the Basel Declaration and recommendations of Wenzhou Medical University Administration Committee of Experimental Animals. The protocol was approved by the Wenzhou Medical University Administration Committee of Experimental Animals (ID Number: wydw2019-650). Ten rats were randomly divided into two groups: the vonoprazan group (n = 5) and control group (n = 5). Both groups were fasted overnight before experiments but were allowed water all the time. The six probe drug mixtures and vonoprazan were dissolved in 0.5% carboxy methyl cellulose sodium (CMC-Na), respectively. The vonoprazan group was administered 5 mg/kg of vonoprazan for 14 days. The control group was administered 0.5% CMC-Na. After 30 min of vonoprazan or 0.5% CMC-Na, on the 14^th^ day, the two groups were treated by gavage at a single dosage of 10 mg/kg for bupropion, dextromethorphan, phenacetin, midazolam, and chlorzoxazone, and of 1 mg/kg for tolbutamide.

Sample Collection and Preparation {#s2_6}
---------------------------------

Blood samples (300 µl) were collected *via* the tail vein at the time points of 0.083, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 h. after gavage. Next, the samples were collected into 1.5-ml centrifuge tubes and were immediately centrifuged for 10 min at 4,000 rpm speed. For every 100 µl of rat plasma was added with 200 µl of acetonitrile in 0.5 μg/ml of IS was added, followed by vortex mixing for one minute. After centrifugation at 13,000 rpm for 15 min, 5 µl of supernatant was prepared for UPLC-MS/MS system to analysis. *In vitro* DDI detection system, the pH was 7.4 and the component of buffer was consisted of 100 mM potassium phosphate.

Statistical Analysis {#s2_7}
--------------------

The GraphPad (version 7.0; GraphPad Software Inc., San Diego, CA, USA) was applied to calculate IC50 values and plot plasma concentration-time curves. The pharmacokinetic parameters using noncompartmental analysis was calculated by DAS (version 3.2.8; Wenzhou Medical University, China). Statistical comparisons within groups were conducted by SPSS (version 25.0; SPSS Inc., Chicago, IL, USA), using Student\'s t-test. A *P*-value \<0.05 was considered statistically significant.

Results {#s3}
=======

Effects of Vonoprazan on the Metabolism of Probe Drugs *In Vitro* {#s3_1}
-----------------------------------------------------------------

Following vonoprazan addition, the metabolism of the four probe drugs midazolam, tolbutamide, dextromethorphan, and bupropion were inhibited to various degrees ([**Figure 2**](#f2){ref-type="fig"}). Their IC~50~ values in rat microsomes were 22.48 µM ([**Figure 2A**](#f2){ref-type="fig"}), 18.34 µM ([**Figure 2B**](#f2){ref-type="fig"}), 3.62 Mm ([**Figure 2C**](#f2){ref-type="fig"}), and 3.68 µM ([**Figure 2D**](#f2){ref-type="fig"}), respectively. By contrast, chlorzoxazone ([**Figure 2E**](#f2){ref-type="fig"}) and phenacetin ([**Figure 2F**](#f2){ref-type="fig"}) displayed no inhibition. The results illustrated that vonoprazan can inhibit the metabolism of midazolam, tolbutamide, dextromethorphan, and bupropion in rat microsomes.

![The inhibitory effect of vonoprazan on midazolam **(A)**, tolbutamide **(B)**, dextromethorphan **(C)**, bupropion **(D)**, chloraoxazone**(E)**, and phenacetin **(F)** for IC50 values in RLMs (values are Mean ± SD, n = 3).](fphar-11-00053-g002){#f2}

Effects of Vonoprazan on the Metabolism of Probe Drugs *In Vivo* {#s3_2}
----------------------------------------------------------------

The statistical analysis results of the mean pharmacokinetic parameters are demonstrated in [**Tables 2**](#T2){ref-type="table"}--[**4**](#T4){ref-type="table"}, which were analyzed by DSA 3.2.8. The mean plasma concentration *versus* time curves of each probe drug in the vonoprazan and control groups are presented in [**Figure 3**](#f3){ref-type="fig"}.

###### 

Pharmacokinetic parameters of probe drugs (midazolam and bupropion) from control group and vonoprazan group rats (mean ± SD, n = 5).

  Parameters    Unit      Midazolam             Bupropion                             
  ------------- --------- --------------------- ----------------- ------------------- -----------------
  AUC ~(0-t)~   ug/L\*h   1,355.69 ± 539.80\*   625.40 ± 194.16   767.76 ± 374.15\*   241.87 ± 105.87
  AUC ~(0-∞)~   ug/L\*h   1,480.79 ± 577.29\*   656.94 ± 198.31   804.11 ± 384.27\*   243.45 ± 106.60
  MRT ~(0-t)~   h         2.35 ± 0.39           1.90 ± 0.60       2.93 ± 0.59         2.72 ± 0.51
  MRT ~(0-∞)~   h         3.11 ± 0.68           2.34 ± 1.12       3.49 ± 1.33         2.78 ± 0.57
  t~1/2z~       h         2.31 ± 0.48           1.85 ± 1.18       2.43 ± 1.13         1.38 ± 0.25
  Tmax          h         0.45 ± 0.11\*         0.18 ± 0.09       0.40 ± 0.14         0.37 ± 0.36
  Vz/F          L/kg      24.50 ± 7.07          39.36 ± 20.44     48.17 ± 19.58       99.13 ± 53.70
  CLz/F         L/h/kg    7.65 ± 2.95\*         16.90 ± 7.15      15.24 ± 7.66\*      51.79 ± 32.61
  Cmax          ug/L      622.13 ± 420.88       335.42 ± 190.55   323.44 ± 197.10\*   97.08 ± 55.54

\*P \< 0.05 indicates statistical difference between the two groups.

###### 

Pharmacokinetic parameters of probe drugs (dextromethorphan and tolbutamide) from control group and vonoprazan group rats (mean ± SD, n = 5).

  Parameters    Unit      Dextromethorphan    Tolbutamide                             
  ------------- --------- ------------------- ----------------- --------------------- -------------------
  AUC ~(0-t)~   ug/L\*h   804.16 ± 205.63\*   318.68 ± 107.33   462,333 ± 103,203\*   248,799 ± 122,431
  AUC ~(0-∞)~   ug/L\*h   842.68 ± 199.30\*   336.61 ± 95.30    484,776 ± 126,240\*   264,335 ± 138,164
  MRT ~(0-t)~   h         3.14 ± 0.47         3.47 ± 0.65       7.92 ± 0.29           7.65 ± 1.24
  MRT ~(0-∞)~   h         3.77 ± 1.04         4.35 ± 1.99       8.88 ± 1.04           8.72 ± 2.10
  t~1/2z~       h         2.57 ± 0.94         2.61 ± 1.47       4.83 ± 1.27           4.99 ± 1.56
  Tmax          h         0.45 ± 0.33         0.75 ± 0.77       3.60 ± 1.34           3.00 ± 1.00
  Vz/F          L/kg      46.04 ± 19.59       125.47 ± 88.46    0.0140 ± 0.0020\*     0.03 ± 0.01
  CLz/F         L/h/kg    12.44 ± 3.12\*      31.91 ± 9.87      0.002 ± 0.001         0.01 ± 0.00
  Cmax          ug/L      275.76 ± 63.90\*    95.96 ± 55.77     36,407 ± 6,755\*      21,791 ± 3,736

\*P \< 0.05 indicates statistical difference between the two groups.

###### 

Pharmacokinetic parameters of probe drugs (chlorzoxazone and phenacetin) from control group and vonoprazan group rats (mean ± SD, n = 5).

  Parameters    Unit      Chlorzoxazone         Phenacetin                                
  ------------- --------- --------------------- --------------------- ------------------- -------------------
  AUC ~(0-t)~   ug/L\*h   73,080.1 ± 12,891.2   89,528.9 ± 10,455.3   4,873.1 ± 2,596.0   5,037.1 ± 2,108.7
  AUC ~(0-∞)~   ug/L\*h   73,138.9 ± 12,884.3   89,629.8 ± 10,476.8   4,891.2 ± 2,581.9   5,043.6 ± 2,107.0
  MRT ~(0-t)~   h         2.16 ± 0.37           2.69 ± 0.79           1.06 ± 0.20         1.12 ± 0.20
  MRT ~(0-∞)~   h         2.17 ± 0.37           2.70 ± 0.80           1.10 ± 0.25         1.13 ± 0.21
  t~1/2z~       h         0.93 ± 0.33           0.93 ± 0.28           0.68 ± 0.31         0.60 ± 0.06
  Tmax          h         0.75 ± 0.35           1.50 ± 1.00           0.30 ± 0.11         0.30 ± 0.11
  Vz/F          L/kg      0.19 ± 0.08           0.15 ± 0.05           2.86 ± 2.41         1.97 ± 0.81
  CLz/F         L/h/kg    0.14 ± 0.03           0.11 ± 0.01           2.65 ± 1.52         2.25 ± 0.80
  Cmax          ug/L      27,449.6 ± 8,245.7    28,500.0 ± 5,519.9    4,798.2 ± 3,104.8   3,865.3 ± 1,020.4

![The pharmacokinetic profiles of midazolam **(A)**, dextromethorphan **(B)**, bupropion **(C)**, chlorzoxazone **(D)**, tolbutamide **(E)**, and phenacetin **(F)** in control group and vonoprazan group rats (n = 5).](fphar-11-00053-g003){#f3}

Midazolam, bupropion, dextromethorphan, and tolbutamide showed significant differences (*P* \< 0.05) in distinct pharmacokinetic parameters compared with the control group, while the parameters of chlorzoxazone and phenacetin were not significantly different. The AUC~0→t~ values of midazolam, bupropion, dextromethorphan, and tolbutamide were all increased greatly, by 1.17-fold, 2.17-fold, 1.52-fold, and 0.86-fold, respectively, compared with that of the control group. Additionally, the AUC~0→∞~ values were elevated by 1.25-fold, 2.30-fold, 1.50-fold, and 0.83-fold, respectively. Specifically, the addition of vonoprazan significantly increased the Tmax of midazolam and the Cmax values of bupropion, dextromethorphan, and tolbutamide by 1.50-fold, 2.33-fold, 1.87-fold, and 0.67-fold, respectively. Additionally, vonoprazan significantly decreased the CLz/F of midazolam, bupropion, dextromethorphan, and the Vz/F of bupropion by 54.7, 70.6, 61.0, and 53.3%, respectively.

These results indicate that vonoprazan has an inhibitory effect on the metabolism of midazolam, bupropion, dextromethorphan, and tolbutamide in rats, agreeing with the results obtained *in vitro*.

Discussion {#s4}
==========

Vonoprazan, a P-CAB drug, was approved for application in the treatment of acid-related diseases in Japan on December 26, 2014 ([@B30]). Previously, proton pump inhibitors (PPIs) were considered the first-in-class available drug to treat acid-related diseases, such as gastroesophageal reflux disease and gastroduodenal ulcers ([@B27]), and has been widely utilized in the eradication therapy of *H. pylori* ([@B3]). The unmet clinical needs of PPIs promote new drug development. Because the high acidic environment in the stomach is established by the gastric H+ and K+-ATPase([@B39]), classical PPIs have been produced previously. P-CABs can both block the H+ and K+-ATPase enzyme and reversibly bind K+ ion ([@B1]), enabling vonoprazan to show long duration and good bioavailability that can be less affected by the pH in the stomach ([@B12]). The better are the physicochemical characteristics, the more frequent are well-designed controlled clinical trials conducted. Thus, vonoprazan has been gradually applied in triple or quadruple regimens as a substitute for PPIs to enhance the antimicrobial effect against *H. pylori* because drug resistance to classical strategies has increased annually ([@B5]). Vonoprazan was confirmed to be superior in the secondary prevention of nonsteroidal anti-inflammatory drug-induced peptic ulcers ([@B21]). Vonoprazan is also thought to potentially show superiority over PPIs in patients who are difficult to treat, given that it can reliably achieve a therapeutically required intragastric pH ([@B31]).

Concerning the pharmacodynamics of vonoprazan, before it entered the market, *in vitro* studies demonstrated that it is mainly metabolized by CYP3A4 and partially by CYP2C19, CYP2B6, CYP2D6, and SULT2A1 ([@B4]). At that time, its inhibitory effect on any CYP isozymes were considered would not to emerge in clinical settings. However, though the distinct CYP2C19 genotypes showed no appreciable correlation with its metabolism in initial study ([@B16]), subsequent trials exhibited dissimilar results ([@B7]), indicating there may be other possible DDIs. Thus, intending to explore as much DDIs as possible, we chose those six probe drugs for wider coverage: phenacetin (CYP1A2), bupropion (CYP2B6), tolbutamide (CYP2C9), dextromethorphan (CYP2D6), midazolam (CYP3A), and chlorzoxazone (CYP2E1). Those similar enzymes also have been detected in other clinical trials ([@B11]). We utilized the system we established before, which is more convincing and reliable. But as rats do not have CYP2C19, the results are limited and it should be paid attention to this, if the trials on human were to be conducted.

This study investigated the potential DDIs *in vitro* by using rat liver microsomes and *in vivo* using performing ultra-performance liquid chromatography-tandem mass spectrometry to detect the metabolites of probe drugs in rat plasma. The *in vitro* results indicated that vonoprazan has direct inhibitory effects on CYP3A4 (IC~50~ = 22.48 µM), CYP2C9 (IC~50~ = 18.34 µM), CYP2D6 (IC~50~ = 3.62 µM), and CYP2B6 (IC~50~ = 3.68 µM), but no effect on CYP1A2 and CYP2E1. These findings partially confirm the results produced using making use of human liver microsomes (HLMs) ([@B23]). Nevertheless, the IC~50~ values in previous studies *via* HLMs were much higher than the maximum plasma concentrations of vonoprazan after therapeutic oral doses; therefore, theoretically, few clinical restraint effects should be considered. However, actual situations are more complex than expected. A previous study reported a reference maximum plasma concentration level in rats of 17 ng/ml ([@B19]), indicating that the threshold value of vonoprazan could be reached and that the metabolism of these four probe drugs could be extended in rats *in vivo*.

Therefore, to further consolidate our results, pharmacokinetic interaction studies in rats *in vivo* were implemented. The main pharmacokinetic parameters (AUC0→t and AUC0→∞) of midazolam, bupropion, dextromethorphan, and tolbutamide were elevated significantly following vonoprazan, indicating vonoprazan indeed constrained their metabolism. Specifically, the oral clearance (CLz/F) of midazolam was decreased while the Tmax was increased, indicating vonoprazan affected midazolam by postponing the exposure and reducing the clearance. Regarding bupropion and dextromethorphan, vonoprazan may lessen the clearance and resulted in a rise in the maximum plasma concentration (Cmax). Regarding tolbutamide, the apparent volume of distribution (Vz/F) declined, implying that the vonoprazan approximately can enhance its binding ability, thus increasing Cmax. Similar to the *in vitro* findings, chlorzoxazone and phenacetin was not affected by vonoprazan. Because the diverse probe drugs represent corresponding CYP enzymes, considering all of the data, the results *in vitro* and *in vivo* were coherent: the vonoprazan can inhibit CYP3A4, CYP2C9, CYP2D6, and CYP2B6 to a distinct extent.

Drug interactions of PPI have been studied a lot and results are quite specific ([@B38]). As a feasible substitute in future, the vonoprazan\'s DDIs deserve explorations. Thus far, the DDI investigation of vonoprazan mainly concerned CYP3A4 and CYP2C19, with unconvincing consequences. In the triple regimens to eradicate H. pylori infection, whether the coadministration of vonoprazan and clarithromycin (CYP3A4 inhibitor) would have a mutual effect remains debatable ([@B14]; [@B29]). Additionally, [@B17] observed that vonoprazan could attenuate the function of clopidogrel, not depending on the CYP2C19 or CYP3A4 genotypes. Other CYP types were also confirmed to not be associated with reducing the antiplatelet effectiveness of both clopidogrel ([@B22]) and prasugrel ([@B24]). It seems the relationship between anti-acid and antiplatelet agents is more intricate. The controversial findings could be due to the heterogeneity of different studies or influenced by other type enzymes noted in this study. The potential inhibitory effects of vonoprazan on CYP2C9, CYP2D6, and CYP2B6 have been revealed in our results but didn\'t be paid much attention in other studies. Considering various common drugs are metabolized by these pathways: warfarin by 3A4 and 2C9 ([@B34]), tricyclic antidepressants by 2D6 ([@B8]), nicotine by 2B6 ([@B32]), it has significant value to verify the authentic DDIs in clinical settings.

Owing to limited condition, we have not applied it to human beings yet. But it is necessary for further study and we will consider to perform it in future, basing on the present results that we get from rats. Furthermore, other inhibitory mechanisms can be explored ([@B42]). Thus, stricter clinical trials will be needed to further confirm these findings.

In summary, our study investigated CYP-based drug-drug interactions both *in vitro* and *in vivo*. The results demonstrated that the vonoprazan could inhibit CYP3A4, CYP2C9, CYP2D6, and CYP2B6, suggesting that the coadministration of vonoprazan and CYP substrates should be performed cautiously in clinical settings.
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